Proximity to Water Pollutant Facilities and Risk of Incident Progressive Supranuclear Palsy
OBJECTIVES: Progressive supranuclear palsy (PSP) is a tauopathy of unknown etiology. Environmental toxin exposure is implicated as a risk factor. The aim of our study was to evaluate whether residential proximity to water pollutant-emitting industrial facilities is associated with incident PSP diagnosis. METHODS: Within the prospective, population-based UK Biobank cohort, we compared incident PSP cases and age- and sex-matched controls by baseline residential proximity to facilities in the European Pollutant Release and Transfer Register (PRTR). RESULTS: Among 221 incident PSP cases (mean [SD] age, 63.0 [5.5] years; 91 women [41.2%]) and 2,249 controls, increased PSP risk was associated with proximity to facilities emitting heavy metals (odds ratio [OR] 1.38; 95% CI 1.03-1.85), pesticides (OR 1.66; 95% CI 1.12-2.46), other organic pollutants (OR 1.52; 95% CI 1.13-2.04), and other inorganic pollutants (OR 1.60; 95% CI 1.19-2.15), after false discovery rate correction. Risk decreased linearly with greater distance (5-10 km), and that residence exceeding 40 years conferred increased risk for heavy metals and organic and inorganic pollutants, unlike shorter residence windows. DISCUSSION: Residential proximity to water pollutant-emitting facilities was associated with incident PSP, with possible evidence of distance-dependent and duration-dependent relationships, supporting a potential role for environmental water pollutants in PSP pathogenesis. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that baseline residential proximity to water pollutant-emitting facilities reported in the 2007 PRTR is associated with a higher risk of subsequent diagnosis of PSP in the UK Biobank.
Authors
- Irene Litvan (ORCID: https://orcid.org/0000-0002-3485-3445)
- Maria Carmela Tartaglia (ORCID: https://orcid.org/0000-0002-5944-8497)
- Marian L. Dale (ORCID: https://orcid.org/0000-0003-1010-982X)
- James Benedict Rowe (ORCID: https://orcid.org/0000-0001-7216-8679)
- Ruth B. Schneider (ORCID: https://orcid.org/0000-0001-8094-4041)
- Christopher D. Stephen (ORCID: https://orcid.org/0000-0002-4727-192X)
- Zoltan K. Mari (ORCID: https://orcid.org/0000-0003-0356-9879)
- Alexander Y. Pantelyat (ORCID: https://orcid.org/0000-0002-6427-7485)
- David G. Coughlin (ORCID: https://orcid.org/0000-0003-4111-0102)
- Anne-Marie A. Wills (ORCID: https://orcid.org/0000-0002-0901-4711)
- Federico E Rodriguez‐Porcel (ORCID: https://orcid.org/0000-0002-7492-5095)
- Lawrence I. Golbe (ORCID: https://orcid.org/0000-0002-4373-3365)
- Tao Xie (ORCID: https://orcid.org/0000-0001-9551-6613)
- Douglas David Gunzler (ORCID: https://orcid.org/0000-0003-3786-8578)
- Charlie Weige Zhao (ORCID: https://orcid.org/0000-0002-8670-0985)
- Burton Scott
Institutions
- Rutgers, The State University of New Jersey (US)
- MetroHealth (US)
- Cleveland Clinic (US)
- University Health Network (CA)
- Harvard University (US)
- Johns Hopkins University (US)
- Medical University of South Carolina (US)
- University of San Diego (US)
- Oregon Health & Science University (US)
- Duke University (US)
- University of Toronto (CA)
- Neurosciences Institute (US)
- MRC Cognition and Brain Sciences Unit (GB)
- University of Cambridge (GB)
- Johns Hopkins Medicine (US)
- Lou Ruvo Brain Institute (US)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- University of California San Diego (US)
- University of Chicago (US)
- University of Chicago Medical Center (US)
- CurePSP (US)
- Mass General Brigham (US)
- University of Rochester (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- Neurology
- Published
- 2026-10-28
- DOI
- https://doi.org/10.1212/wnl.0000000000218750
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00